Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Australian Stock Exchange  >  CSL Limited    CSL   AU000000CSL8

CSL LIMITED

(CSL)
  Report
End-of-day quote. End-of-day quote Australian Stock Exchange - 02/26
262.59 AUD   -2.83%
02/22Australia shares slip on tech, healthcare losses
RE
02/21Australia shares flat as mining gains offset healthcare losses
RE
02/18Australia shares track Wall Street lower, miners and banks weigh
RE
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Australian Stock Exchange
02/22/2021 02/23/2021 02/24/2021 02/25/2021 02/26/2021 Date
267.79 267.96 267.96 270.25 262.59 Last
1524227 839899 696063 789871 1235330 Volume
-2.42% +0.06% 0.00% +0.85% -2.83% Change
Financials (USD)
Sales 2021 10 063 M - -
Net income 2021 2 284 M - -
Net Debt 2021 4 198 M - -
P/E ratio 2021 40,3x
Yield 2021 1,01%
Sales 2022 10 610 M - -
Net income 2022 2 391 M - -
Net Debt 2022 4 099 M - -
P/E ratio 2022 38,5x
Yield 2022 1,14%
Capitalization 92 037 M 92 178 M -
EV / Sales 2021 9,56x
EV / Sales 2022 9,06x
Nbr of Employees 27 000
Free-Float 99,8%
More Financials
Company
CSL Limited is an Australia-based biotechnology company engaged in the developing and delivering medicines that treat people with rare diseases. It offers treatments for people who are living with conditions in the immunology and neurology; haematology and thrombosis; cardiovascular and metabolic; respiratory, and transplant therapeutic areas. Its segment includes CSL Behring and Seqirus. CSL Behring segment... 
More about the company
Notations Surperformance© of CSL Limited
Trading Rating : Investor Rating :
More Ratings
All news about CSL LIMITED
02/22Australia shares slip on tech, healthcare losses
RE
02/21Australia shares flat as mining gains offset healthcare losses
RE
02/18Australia shares track Wall Street lower, miners and banks weigh
RE
02/18Australia shares end flat as energy stocks weigh; Treasury Wine shines
RE
02/18Australian Shares Struggle for Direction Amid Mixed Earnings Results; Unemplo..
MT
02/17CSL : Raises Interim Dividend as July-December 2020 Profit Grows; Shares Jump 3%
MT
02/17Strong blue-chip earnings nudge Australia shares higher
RE
02/17Australia shares flat on mixed corporate earnings, miners weigh
RE
02/17CSL : 1st Half Net Profit Surges, Warns of Plasma-Collection Issues
DJ
02/17ASTRAZENECA : Australia's CSL half-year profit jumps 45% on strong blood plasma ..
RE
02/17CSL : Australia's CSL reports 45% jump in half-year profit
RE
02/17GLOBAL MARKETS LIVE: Shopify, Rio Tinto, Baidu...
02/17Australia shares slip as gold miners weigh, BHP hits record high
RE
02/14CSL : COVID-19 Update
PU
02/11CSL : Local Manufacturing of COVID-19 Vaccine Update
PU
More news
News in other languages on CSL LIMITED
02/17"La seule raison d'être baissier, c'est qu'il n'y a pas de raison d'être bais..
02/17EN DIRECT DES MARCHES : Kering, Nexans, Eramet, Air Liquide, Danone, Air France,..
02/15BHP : bénéfice semestriel en hausse grâce aux cours du minerai de fer
2020MÄRKTE ASIEN/Uneinheitlich - Kospi erneut mit Rekord
2020MÄRKTE ASIEN/Uneinheitlich - Brent-Ölpreis über 50 USD
More news
Analyst Recommendations on CSL LIMITED
More recommendations
Chart CSL LIMITED
Duration : Period :
CSL Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CSL LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 235,00 $
Last Close Price 202,27 $
Spread / Highest target 28,4%
Spread / Average Target 16,2%
Spread / Lowest Target -5,05%
EPS Revisions
Managers and Directors
NameTitle
Paul Roger Perreault Chief Executive Officer, Executive Director & MD
Joy Carolyn Linton Chief Financial Officer
Brian Anthony McNamee Chairman
Andrew Cuthbertson Chief Scientific Officer & Executive Director
William Mezzanotte Chief Medical Officer, EVP & Head-R&D
Sector and Competitors
1st jan.Capitalization (M$)
CSL LIMITED-7.27%92 178
WUXI BIOLOGICS (CAYMAN) INC.-6.57%52 131
SAMSUNG BIOLOGICS CO.,LTD.-9.20%43 986
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.17.96%43 127
BIOGEN INC.11.44%41 569
ALEXION PHARMACEUTICALS, INC.-2.23%33 561